Novel amides of 1,1-bis-(carboxymethylthio)-1-arylethanes: Synthesis, characterization, acetylcholinesterase, butyrylcholinesterase, and carbonic anhydrase inhibitory properties

J Biochem Mol Toxicol. 2018 Sep;32(9):e22191. doi: 10.1002/jbt.22191. Epub 2018 Jul 10.

Abstract

The thiolation reaction was carried out in a benzene solution at 80°C and p-substituted ketones and mercaptoacetic acid in a molar ratio (1:4) of in the presence of a catalytic amount of toluene sulfonic acids. The enzyme inhibition activities of the novel amides of 1,1-bis-(carboxymethylthio)-1-arylethanes derivatives were investigated. These novel amides of 1,1-bis-(carboxymethylthio)-1-arylethanes derivatives showed good inhibitory action against acetylcholinesterase (AChE) butyrylcholinesterase (BChE), and human carbonic anhydrase I and II isoforms (hCA I and II). AChE inhibitors, interacting with the enzyme as their primary target, are applied as relevant drugs and toxins. Many clinically established drugs are carbonic anhydrase inhibitors, and it is highly anticipated that many more will eventually find their way into the market. The novel synthesized compounds inhibited AChE and BChE with Ki values in the range of 0.64-1.47 nM and 9.11-48.12 nM, respectively. On the other hand, hCA I and II were effectively inhibited by these compounds, with Ki values between 63.27-132.34 and of 29.63-127.31 nM, respectively.

Keywords: acetylcholinesterase; carbonic anhydrase; enzyme inhibition; mercaptoacetic acid; p-substituted ketones.

Publication types

  • Comparative Study

MeSH terms

  • Acetazolamide / pharmacology
  • Acetylcholinesterase / chemistry
  • Acetylcholinesterase / metabolism
  • Amides / chemical synthesis
  • Amides / chemistry
  • Amides / pharmacology*
  • Animals
  • Anticonvulsants / chemical synthesis
  • Anticonvulsants / chemistry
  • Anticonvulsants / pharmacology
  • Antiparkinson Agents / chemical synthesis
  • Antiparkinson Agents / chemistry
  • Antiparkinson Agents / pharmacology
  • Butyrylcholinesterase / chemistry
  • Butyrylcholinesterase / metabolism
  • Carbonic Anhydrase I / antagonists & inhibitors
  • Carbonic Anhydrase I / chemistry
  • Carbonic Anhydrase I / metabolism
  • Carbonic Anhydrase II / antagonists & inhibitors
  • Carbonic Anhydrase II / metabolism
  • Carbonic Anhydrase Inhibitors / chemical synthesis
  • Carbonic Anhydrase Inhibitors / chemistry
  • Carbonic Anhydrase Inhibitors / pharmacology*
  • Cholinesterase Inhibitors / chemical synthesis
  • Cholinesterase Inhibitors / chemistry
  • Cholinesterase Inhibitors / pharmacology*
  • Drug Design
  • Electrophorus
  • Enzyme Inhibitors / chemical synthesis
  • Enzyme Inhibitors / chemistry
  • Enzyme Inhibitors / pharmacology*
  • Horses
  • Humans
  • Kinetics
  • Molecular Structure
  • Nootropic Agents / chemical synthesis
  • Nootropic Agents / chemistry
  • Nootropic Agents / pharmacology
  • Proton Magnetic Resonance Spectroscopy
  • Sulfhydryl Compounds / chemical synthesis
  • Sulfhydryl Compounds / chemistry
  • Sulfhydryl Compounds / toxicity*

Substances

  • Amides
  • Anticonvulsants
  • Antiparkinson Agents
  • Carbonic Anhydrase Inhibitors
  • Cholinesterase Inhibitors
  • Enzyme Inhibitors
  • Nootropic Agents
  • Sulfhydryl Compounds
  • Acetylcholinesterase
  • Butyrylcholinesterase
  • Carbonic Anhydrase I
  • Carbonic Anhydrase II
  • CA1 carbonic anhydrase, human
  • Acetazolamide